GPR175 Inhibitors
Chemical inhibitors of GPR175 include a range of beta-adrenergic receptor antagonists that indirectly influence the functional activity of this G protein-coupled receptor. Propranolol, a non-selective beta-blocker, is known for its capacity to inhibit beta-adrenergic receptors, which can reduce the cellular responses to thyroid hormone derivatives. Since GPR175 responds to thyroid hormone levels, the blockade of these receptors by Propranolol can functionally inhibit the downstream effects that are mediated through GPR175. Similarly, Sotalol and Nadolol, both non-selective beta-blockers, and Timolol, a non-selective beta-adrenergic antagonist, can diminish the adrenergic effects regulated by thyroid hormones and therefore attenuate GPR175 signaling processes. Metoprolol and Atenolol, which are selective beta1-blockers, can specifically inhibit the cardiac responses to thyroid hormone derivatives, thereby indirectly inhibiting GPR175 activity in adrenergic signaling pathways within the heart.
Furthermore, Esmolol, a cardioselective beta1-blocker, reduces the cardiac responses to thyroid hormones, potentially inhibiting GPR175's effects on cardiac adrenergic signaling. Bisoprolol, another selective beta1-adrenergic receptor antagonist, operates in a similar fashion by diminishing the influence of thyroid hormone derivatives on the heart, which in turn leads to functional inhibition of GPR175. Carvedilol, with its non-selective beta-adrenergic blocking and additional alpha-blocking activity, can inhibit the effects of thyroid hormone derivatives on both alpha and beta-adrenergic receptors, thereby functionally inhibiting GPR175's role in these pathways. Labetalol, with its dual action as both a beta and alpha1-adrenergic antagonist, reduces the cellular effects of thyroid hormones, thus potentially reducing GPR175's functional activity. Nebivolol, which selectively inhibits beta1-receptors, and Pindolol, a non-selective beta-blocker with partial agonist activity, can also functionally inhibit GPR175 by blocking the response of downstream signaling pathways to thyroid hormone derivatives, which are known to interact with GPR175.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective beta-adrenergic receptor antagonist. GPR175 (Tpra1) is a G protein-coupled receptor that responds to thyroid hormone derivatives, which can influence adrenergic signaling. Propranolol, by blocking beta-adrenergic receptors, can reduce the cellular responses to thyroid hormone derivatives, thereby functionally inhibiting the downstream effects mediated by GPR175. | ||||||
Sotalol hydrochloride | 959-24-0 | sc-203699 sc-203699A | 10 mg 50 mg | $68.00 $251.00 | 3 | |
Sotalol is a beta-blocker with antiarrhythmic properties. Similar to propranolol, it blocks beta-adrenergic receptors and can diminish the effects of thyroid hormone derivatives on these receptors, leading to a functional inhibition of GPR175's influence on adrenergic signaling pathways. | ||||||
(S)-Timolol Maleate | 26921-17-5 | sc-203297 sc-203297A | 100 mg 250 mg | $61.00 $126.00 | ||
Timolol is another beta-adrenergic receptor antagonist that can prevent the adrenergic effects regulated by thyroid hormones. Since GPR175 is sensitive to thyroid hormone levels, timolol's antagonistic action on beta-adrenergic receptors may attenuate the signaling processes involving GPR175. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $107.00 $243.00 | 3 | |
Metoprolol is a selective beta1-blocker, which can specifically inhibit the cardiac effects of thyroid hormone derivatives. By doing so, it can indirectly inhibit the functional activity of GPR175, which is modulated by thyroid hormones. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $79.00 $416.00 | 1 | |
Atenolol is a selective beta1-adrenergic receptor antagonist. It can functionally inhibit GPR175 by blocking the action of thyroid hormone derivatives that may act through the beta1-adrenergic pathway, which in turn could be involved in the signaling cascade of GPR175. | ||||||
Nadolol | 42200-33-9 | sc-253175 | 1 g | $184.00 | ||
Nadolol is a non-selective beta-adrenergic receptor antagonist. By inhibiting the receptors that thyroid hormone derivatives may act upon, nadolol can indirectly suppress the influence of GPR175 on these signaling pathways. | ||||||
Esmolol Hydrochloride | 81161-17-3 | sc-211424 | 10 mg | $149.00 | 1 | |
Esmolol is a cardioselective beta1-adrenergic receptor blocker. Its action can reduce the cardiac responses to thyroid hormones, and since GPR175 is responsive to such hormones, esmolol can functionally inhibit the protein's effects on cardiac adrenergic signaling. | ||||||
Bisoprolol | 66722-44-9 | sc-278792 | 25 mg | $208.00 | ||
Bisoprolol, a selective beta1-adrenergic receptor antagonist, can diminish the influence of thyroid hormone derivatives on the heart. This blockade can lead to a functional inhibition of GPR175, as it is a receptor known to respond to these hormones. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol is a non-selective beta-adrenergic blocker with alpha-blocking activity. It can inhibit the effects of thyroid hormone derivatives on both alpha and beta-adrenergic receptors, which could indirectly lead to a functional inhibition of GPR175's role in these pathways. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
Labetalol is both a beta-adrenergic antagonist and an alpha1-adrenergic antagonist. This dual action can inhibit the cellular effects of thyroid hormone derivatives, potentially reducing the functional activity of GPR175 in adrenergic signaling. | ||||||